Furthermore, based on previous experience with BRAF and MEK inhibitors, it is plausible that not all BRAF-V600E melanomas are uniformly sensitive to ERK inhibition; hence, it is important to identify molecular markers associated with response and resistance. Here, MAP2K7 is linked to melanoma.